AnBogen Therapeutics, Inc. is a precision oncology company that develops therapies for cancer treatment. AnBogen leverages diverse roots, scientific knowledge, and expertise in drug discovery and development to create therapies aimed at transforming cancer treatment.

AnBogen Therapeutics, Inc.

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs.

Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development. 


AnBogen Therapeutics

Anbogen Therapeutics is pleased to announce the successful closing of a USD 7.3M oversubscribed A+ round financing, bringing our total Series A funding to USD 19.8M. This funding will advance the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer.

Read the complete news release here: https://reurl.cc/MOEGQ3
#SeriesA+ #AnbogenTherapeutics #ABT301 #immunecheckpointinhibitors

Delighted to announce the successful completion of Anbogen Therapeutics' Series A, with USD 12.5 million raised. Gratitude to our investors for their support as we advance in developing precision anti-cancer drugs. Read the complete news release here: https://lnkd.in/gpacKFWF
#SeriesA #Biotech #Innovation #AnbogenTherapeutics

Happy New Year from all of us at Anbogen! As we enter 2024, we're not only celebrating the possibilities ahead but also eagerly anticipating sharing more of our precision drug development progress with you this year. Wishing everyone a year filled with success, health, and exciting discoveries!
#ABT-101 #ABT-301 #ABT-202

COM:ANBOGEN

AnBogen Therapeutics, Inc.